

BTG

Pharma & biotech

22 November 2018

The BTG acquisition: Small fly, big ointment

Following our note on BTG's interim results, the proposed £3.3bn all-cash acquisition by Boston Scientific was announced. Further, on 21 November, BTG and its partner Johnson & Johnson (J&J) failed to prevent the launch of generic competition to Zytiga (28% of BTG's H1 revenue). We examine the potential impact of generic Zytiga on the transaction.

Logical acquisition of interventional volume

US medical device company Boston Scientific announced the recommended offer for BTG of 840p in cash or £3.3bn. There are no break-up fees for UK-listed takeovers and further details on the terms of the transaction have not yet appeared in Boston's SEC [filings](#). The 37% premium to BTG's 19 November share price should be warmly welcomed by at least the 75% of the shareholders required to approve the transaction.

Are imminent Zytiga generics a complication?

One of the bear points from our previous [note](#) was the potential for generic competition to Zytiga (abiraterone) – a blockbuster oral drug to treat prostate cancer. The day after the proposed acquisition of BTG by Boston Scientific was announced, a US Appeals Court ruling allowed generic abiraterone launches while the invalidation of Zytiga's last valid US patent is being appealed.

The effect of Zytiga generics on the acquisition

The key reason for Boston's acquisition of BTG was to add volume and therapeutic breadth to its interventional medicine franchise (c 35% of BTG's total H1 revenue). The royalties from Zytiga are non-core to a medical device company and their divestment after completion may already have been investigated. It is not yet possible to know if Zytiga generics represented a material adverse event for the deal, but the risk to the whole transaction is probably small, although perhaps not negligible in light of there being no break-up fee. A renegotiation on the price of the transaction would probably require a new agreement and, with Boston already having secured funding for the acquisition, we view such a move as unlikely.

Valuation: Academic after Boston's acquisition

Based on I/B/E/S estimates before the acquisition was announced, BTG traded at a FY19 P/E of 17.3x, which we argued was probably more a reflection of the uncertainty of BTG's future revenues, including the Zytiga royalties. Since the announced acquisition by Boston, this multiple has risen to 23.2x.

Consensus estimates

Year end	Revenue (\$m)	PBT (\$m)	EPS (\$)	DPS (c)	P/E* (x)	Yield (%)
03/17	742.9	134.1	0.30	N/A	35.6	N/A
03/18	822.3	212.0	0.43	N/A	24.8	N/A
03/19e	967.8	269.2	0.46	N/A	23.2	N/A
03/20e	965.5	285.3	0.47	N/A	22.7	N/A

Source: Company data, Thomson Reuters I/B/E/S estimates. Note: *PE values 17/18 are averages.

Price 828p

Market cap £3,206m

£:US\$1.29

Share price graph



Share details

Code	BTG
Listing	LSE
Shares in issue	387.1m

Business description

BTG is a medical technology company with products for minimally invasive procedures in oncology patients and in vascular medicine. BGT was originally a technology licensing company that licensed IP and collected pharmaceutical royalties on products such as Campath and Zytega, but more recently, BTG has grown through the acquisitions of Protherics and Novate Medical. Boston Scientific has proposed to acquire BTG.

Bull

- One of the few public UK life sciences companies that is profitable.
- \$285m of cash at the end of H119.
- Diversified portfolio of product segments and licensing revenues.

Bear

- Interventional medicine is a commoditised market with bigger players influencing market share.
- Lower-cost competition to CroFab could intensify.
- Genericisation of Zytega in the medium term.

Analyst

Dr Andy Smith +44 (0)20 3077 5700

healthcare@edisongroup.com

EDISON QUICKVIEWS ARE NORMALLY ONE OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.

General disclaimer and copyright

This report has been prepared and issued by Edison. Edison Investment Research standard fees are £49,500 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the Edison analyst at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out of or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2018 Edison Investment Research Limited (Edison). All rights reserved FTSE International Limited ("FTSE") © FTSE 2018. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd who holds an Australian Financial Services Licence (Number: 427484). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

Neither this document and associated email (together, the "Communication") constitutes or form part of any offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities, nor shall it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. Any decision to purchase shares in the Company in the proposed placing should be made solely on the basis of the information to be contained in the admission document to be published in connection therewith.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document (nor will such persons be able to purchase shares in the placing).

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Neither this Communication nor any copy (physical or electronic) of it may be (i) taken or transmitted into the United States of America, (ii) distributed, directly or indirectly, in the United States of America or to any US person (within the meaning of regulations Regulation S made under the US Securities Act 1933, as amended), (iii) taken or transmitted into or distributed in Canada, Australia, the Republic of Ireland or the Republic of South Africa or to any resident thereof, except in compliance with applicable securities laws, (iv) taken or transmitted into or distributed in Japan or to any resident thereof for the purpose of solicitation or subscription or offer for sale of any securities or in the context where the distribution thereof may be construed as such solicitation or offer, or (v) taken or transmitted into any EEA state other than the United Kingdom. Any failure to comply with these restrictions may constitute a violation of the securities laws or the laws of any such jurisdiction. The distribution of this Communication in or into other jurisdictions may be restricted by law and the persons into whose possession this document comes should inform themselves about, and observe, any such restrictions.